CD34 augmentation improves allogeneic T cell-depleted bone marrow engraftment

S. J. Noga, A. Seber, Janice Davis Sproul, R. J. Berenson, Georgia Boyce Vogelsang, H. G. Braine, A. D. Hess, D. Marcellus, C. A. Miller, S. J. Sharkis, S. N. Goodman, G. W. Santos, Richard J Jones

Research output: Contribution to journalArticle

Abstract

T cell depletion (TCD) performed by elutriation has decreased the incidence of acute and chronic graft-versus-host disease (GvHD) following bone marrow transplantation (BMT). However, as with all forms of TCD, patients may experience graft failure (10%), delayed engraftment, and mixed chimerism. Because 66%-75% of the CD34+ cells coseparate with the small lymphocytes, which are removed by elutriation, we designed a phase I trial in HLA-identical siblings to determine if the readdition of these previously lost small CD34+ cells would improve elutriation's engraftment kinetics. CD34+ cells were isolated from the small cell fraction of 10 consecutive donor grafts and infused into the recipients along with the TCD graft. The positively selected product had a mean T cell content of 1.2 x 105/kg and was 80% CD34+, doubling the CD34+ content of the graft. All patients engrafted promptly with a median time to 500 neutrophils/mm3, untransfused 50,000 platelets/mm3, and discharge from the hospital of 19 (range-10-25), 24 (14-52), and 24 (18-29) days, respectively. Acute GvHD occurred in 2 patients, and no patient had chronic GvHD. Augmenting stem cell dose may be an efficient and safe alternative for overcoming TCD-associated delayed engraftment and graft failure, rather than increasing immunosuppression.

Original languageEnglish (US)
Pages (from-to)151-157
Number of pages7
JournalJournal of Hematotherapy
Volume7
Issue number2
StatePublished - 1998

Fingerprint

Bone Marrow
T-Lymphocytes
Transplants
Graft vs Host Disease
Chimerism
Bone Marrow Transplantation
Immunosuppression
Siblings
Neutrophils
Stem Cells
Blood Platelets
Tissue Donors
Lymphocytes
Incidence

ASJC Scopus subject areas

  • Hematology
  • Immunology

Cite this

CD34 augmentation improves allogeneic T cell-depleted bone marrow engraftment. / Noga, S. J.; Seber, A.; Davis Sproul, Janice; Berenson, R. J.; Vogelsang, Georgia Boyce; Braine, H. G.; Hess, A. D.; Marcellus, D.; Miller, C. A.; Sharkis, S. J.; Goodman, S. N.; Santos, G. W.; Jones, Richard J.

In: Journal of Hematotherapy, Vol. 7, No. 2, 1998, p. 151-157.

Research output: Contribution to journalArticle

Noga, SJ, Seber, A, Davis Sproul, J, Berenson, RJ, Vogelsang, GB, Braine, HG, Hess, AD, Marcellus, D, Miller, CA, Sharkis, SJ, Goodman, SN, Santos, GW & Jones, RJ 1998, 'CD34 augmentation improves allogeneic T cell-depleted bone marrow engraftment', Journal of Hematotherapy, vol. 7, no. 2, pp. 151-157.
Noga, S. J. ; Seber, A. ; Davis Sproul, Janice ; Berenson, R. J. ; Vogelsang, Georgia Boyce ; Braine, H. G. ; Hess, A. D. ; Marcellus, D. ; Miller, C. A. ; Sharkis, S. J. ; Goodman, S. N. ; Santos, G. W. ; Jones, Richard J. / CD34 augmentation improves allogeneic T cell-depleted bone marrow engraftment. In: Journal of Hematotherapy. 1998 ; Vol. 7, No. 2. pp. 151-157.
@article{39d703bfd81c47fc8186dac8dab0747c,
title = "CD34 augmentation improves allogeneic T cell-depleted bone marrow engraftment",
abstract = "T cell depletion (TCD) performed by elutriation has decreased the incidence of acute and chronic graft-versus-host disease (GvHD) following bone marrow transplantation (BMT). However, as with all forms of TCD, patients may experience graft failure (10{\%}), delayed engraftment, and mixed chimerism. Because 66{\%}-75{\%} of the CD34+ cells coseparate with the small lymphocytes, which are removed by elutriation, we designed a phase I trial in HLA-identical siblings to determine if the readdition of these previously lost small CD34+ cells would improve elutriation's engraftment kinetics. CD34+ cells were isolated from the small cell fraction of 10 consecutive donor grafts and infused into the recipients along with the TCD graft. The positively selected product had a mean T cell content of 1.2 x 105/kg and was 80{\%} CD34+, doubling the CD34+ content of the graft. All patients engrafted promptly with a median time to 500 neutrophils/mm3, untransfused 50,000 platelets/mm3, and discharge from the hospital of 19 (range-10-25), 24 (14-52), and 24 (18-29) days, respectively. Acute GvHD occurred in 2 patients, and no patient had chronic GvHD. Augmenting stem cell dose may be an efficient and safe alternative for overcoming TCD-associated delayed engraftment and graft failure, rather than increasing immunosuppression.",
author = "Noga, {S. J.} and A. Seber and {Davis Sproul}, Janice and Berenson, {R. J.} and Vogelsang, {Georgia Boyce} and Braine, {H. G.} and Hess, {A. D.} and D. Marcellus and Miller, {C. A.} and Sharkis, {S. J.} and Goodman, {S. N.} and Santos, {G. W.} and Jones, {Richard J}",
year = "1998",
language = "English (US)",
volume = "7",
pages = "151--157",
journal = "Stem Cells and Development",
issn = "1547-3287",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - CD34 augmentation improves allogeneic T cell-depleted bone marrow engraftment

AU - Noga, S. J.

AU - Seber, A.

AU - Davis Sproul, Janice

AU - Berenson, R. J.

AU - Vogelsang, Georgia Boyce

AU - Braine, H. G.

AU - Hess, A. D.

AU - Marcellus, D.

AU - Miller, C. A.

AU - Sharkis, S. J.

AU - Goodman, S. N.

AU - Santos, G. W.

AU - Jones, Richard J

PY - 1998

Y1 - 1998

N2 - T cell depletion (TCD) performed by elutriation has decreased the incidence of acute and chronic graft-versus-host disease (GvHD) following bone marrow transplantation (BMT). However, as with all forms of TCD, patients may experience graft failure (10%), delayed engraftment, and mixed chimerism. Because 66%-75% of the CD34+ cells coseparate with the small lymphocytes, which are removed by elutriation, we designed a phase I trial in HLA-identical siblings to determine if the readdition of these previously lost small CD34+ cells would improve elutriation's engraftment kinetics. CD34+ cells were isolated from the small cell fraction of 10 consecutive donor grafts and infused into the recipients along with the TCD graft. The positively selected product had a mean T cell content of 1.2 x 105/kg and was 80% CD34+, doubling the CD34+ content of the graft. All patients engrafted promptly with a median time to 500 neutrophils/mm3, untransfused 50,000 platelets/mm3, and discharge from the hospital of 19 (range-10-25), 24 (14-52), and 24 (18-29) days, respectively. Acute GvHD occurred in 2 patients, and no patient had chronic GvHD. Augmenting stem cell dose may be an efficient and safe alternative for overcoming TCD-associated delayed engraftment and graft failure, rather than increasing immunosuppression.

AB - T cell depletion (TCD) performed by elutriation has decreased the incidence of acute and chronic graft-versus-host disease (GvHD) following bone marrow transplantation (BMT). However, as with all forms of TCD, patients may experience graft failure (10%), delayed engraftment, and mixed chimerism. Because 66%-75% of the CD34+ cells coseparate with the small lymphocytes, which are removed by elutriation, we designed a phase I trial in HLA-identical siblings to determine if the readdition of these previously lost small CD34+ cells would improve elutriation's engraftment kinetics. CD34+ cells were isolated from the small cell fraction of 10 consecutive donor grafts and infused into the recipients along with the TCD graft. The positively selected product had a mean T cell content of 1.2 x 105/kg and was 80% CD34+, doubling the CD34+ content of the graft. All patients engrafted promptly with a median time to 500 neutrophils/mm3, untransfused 50,000 platelets/mm3, and discharge from the hospital of 19 (range-10-25), 24 (14-52), and 24 (18-29) days, respectively. Acute GvHD occurred in 2 patients, and no patient had chronic GvHD. Augmenting stem cell dose may be an efficient and safe alternative for overcoming TCD-associated delayed engraftment and graft failure, rather than increasing immunosuppression.

UR - http://www.scopus.com/inward/record.url?scp=0031977635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031977635&partnerID=8YFLogxK

M3 - Article

C2 - 9597572

AN - SCOPUS:0031977635

VL - 7

SP - 151

EP - 157

JO - Stem Cells and Development

JF - Stem Cells and Development

SN - 1547-3287

IS - 2

ER -